Home > Resources > Whitepapers > Five Ways to Streamline Building Manufacturing Systems for Biotech and Pharmaceutical Industries

Five Ways to Streamline Building Manufacturing Systems for Biotech and Pharmaceutical Industries

May 12, 2016

Today’s biotech and pharmaceutical production facilities must drive faster times to market and greater profitability for new products by boosting production yields and accelerating commercialization and scaling of capacityRising healthcare demand worldwide is driving the need for expanded manufacturing capacity in the biotech and pharmaceutical industries. Aging populations. Soaring rates of chronic lifestyle diseases. Emerging middle-classes in developing nations. Treatment and technology advancements. All of these are factors some analysts expect to keep life sciences industries growing faster than the world’s GDP in years to come.

Spotlight

Ascom

Ascom is a global solutions provider focused on healthcare ICT and mobile workflow solutions. The vision of Ascom is to close digital information gaps allowing for the best possible decisions – anytime and anywhere.

OTHER WHITEPAPERS

HIGH THROUGHPUT AAV VIRAL TITERING USING NANOPLATE-BASED DIGITAL PCR

whitePaper | December 22, 2022

Determining the physical titer of viral vectors has typically been accomplished using digital droplet PCR (ddPCR). Droplet-based methods, however, are challenged by matrix effects and long analysis times (up to 7 hours).

The affordability hurdle for gene therapies

whitePaper | October 12, 2022

Advanced therapy medicinal products cell and gene therapies offer tremendous hope for patients either by actually curing serious diseases or by alleviating suffering.

Document quality control emerges as a discipline in its own right

whitePaper | November 19, 2022

Compiling a quality regulatory submission is a basic requirement for biopharmaceutical companies. Poor quality documents could lead to rejection of a regulatory application,

Benefit-Risk Considerations for Product Quality Assessments; Guidance for Industry; DRAFT GUIDANCE

whitePaper | May 10, 2022

This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessments of chemistry, manufacturing, and controls (CMC)2 19 information 20 submitted for FDA assessment as part of original new drug applications (NDAs) under section

A Review of RNA Analysis using the Agilent AutomatedElectrophoresis Portfolio

whitePaper | July 15, 2022

Good-quality RNA is crucial to the success of many downstream applications, including qPCR, microarray analysis, and RNA sequencing. Agilent automated

Biopharmaceutical Sector

whitePaper | May 29, 2023

tronger than expected US inflation and a bump in consumer spending have fuelled worldwide expectations that interest rates will go higher, as predictions about future monetary policy rapidly shift.